TABLE 4.
The pharmacokinetics of TBMS-1.
| Drugs/Administration | Species | Dose | Detail | References |
|---|---|---|---|---|
| TBMS-Ⅰ, i.v | Rats | 5 mg/kg | t1/2β = 6.70 ± 1.90 h; CL = 0.080 ± 0.027 L/(h kg); V = 0.106 ± 0.039 l/kg | Liang et al. (2007) |
| TBMS-Ⅰ, p.o | Rats | 50 mg/kg | Tmax = 2.75 ± 0.96 h; the absolute oral bioavailability was 0.23 ± 0.13% | Liang et al. (2007) |
| TBMS-Ⅰ, p.o | Rats | 50 mg/kg | Cmax = 1,342 ± 404.50 ng/ml; Tmax = 2.85 ± 1.69 h; AUC(0–24h) and AUC(0-∞) were 8,800.03 ± 2,282.47, and 9,904.41 ± 3,447.84 mg/L*h, respectively; MRT(0–24h) = 7.02 ± 1.85 h and the terminal half-life (t1/2) = 4.60 ± 3.88 h | Li et al. (2018) |
| TBMS-Ⅰ, i.v | ICR mice | 5 mg/kg | t1/2z = 6.8 ± 5.6 h | Chen et al. (2018) |
| TBMS-Ⅰ, p.o | ICR mice | 20 mg/kg | t1/2z = 2.3 ± 0.5 h; Tmax = 1.8 ± 1.3 h; the absolute availability was 1.0% | Chen et al. (2018) |
| TBMS-Ⅰ, i.m | Mice | 20 mg/kg | Tissue concentration: liver > spleen > blood > lung > heart > kidney > brain; the binding rates of TBMS-Ⅰ with plasma, liver and kidney tissue proteins were 17.1%, 28.1%, and 20.35%, respectively | Wang et al. (1994) |